NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
J Natl Compr Canc Netw
; 20(2): 106-117, 2022 02.
Article
in En
| MEDLINE
| ID: mdl-35130502
ABSTRACT
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts meets on an annual basis to update the recommendations. These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
Type of study:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Natl Compr Canc Netw
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article